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Several posttranslational modiﬁcations act
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GABAA receptors (GABAARs) mediate the majority of fast inhibitory neurotransmission in
the brain via synergistic association with the postsynaptic scaffolding protein gephyrin and its
interaction partners. However, unlike their counterparts at glutamatergic synapses, gephyrin
and its binding partners lack canonical protein interaction motifs; hence, the molecular basis
for gephyrin scaffolding has remained unclear. In this study, we identify and characterize
two new posttranslational modiﬁcations of gephyrin, SUMOylation and acetylation. We
demonstrate that crosstalk between SUMOylation, acetylation and phosphorylation pathways
regulates gephyrin scaffolding. Pharmacological intervention of SUMO pathway or transgenic
expression of SUMOylation-deﬁcient gephyrin variants rescued gephyrin clustering in CA1 or
neocortical neurons of Gabra2-null mice, which otherwise lack gephyrin clusters, indicating
that gephyrin SUMO modiﬁcation is an essential determinant for scaffolding at GABAergic
synapses. Together, our results demonstrate that concerted modiﬁcations on a protein
scaffold by evolutionarily conserved yet functionally diverse signalling pathways facilitate
GABAergic transmission.
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S
mall ubiquitin-like modiﬁer (SUMO) conjugation to
proteins is a widespread posttranslational modiﬁcation
(PTM) mechanism, which remarkably expands their
structural and functional properties1–3. The SUMO conjugation
pathway includes three SUMO isoforms (SUMO1/2/3); one E1
enzyme complex (SAE1/2); one E2 enzyme (UBC9); numerous E3
ligases, including members of the PIAS family (PIAS1, 2a, 2b, 3
and 4)4,5; and six deSUMOylating enzymes of the SENP family
(SENP1, 2, 3, 5, 6, 7)6. Rapid deSUMOylation compared with
SUMOylation can shift the equilibrium resulting in low steady-
state level of SUMOylated proteins.
Although upstream signals strongly inﬂuence the ratio of
SUMOylated versus deSUMOylated proteins, the downstream
effects of SUMOylation usually involve altered interactions of
modiﬁed proteins with other macromolecules, including proteins,
DNA or RNA6, causing long-lasting changes in cellular function.
Furthermore, cross-talk between different PTMs, such as
phosphorylation-dependent SUMOylation or competition
between SUMOylation and acetylation of the same lysine
residues on speciﬁc substrates, expands this repertoire even
further and allows rapid switches in protein functional states
under the inﬂuence of a variety of signalling cascades6–10.
In neurons, SUMO conjugation of cytoplasmic and membrane
proteins regulates many aspects of cell physiology and synaptic
function in health and disease11,12. In particular, at glutamatergic
synapses, SUMOylation of GluK2, Kv2.1, CASK and Arc
inﬂuences both synapse formation and plasticity12,13. There is
currently little knowledge about the occurrence and functional
implications of SUMOylation at GABAergic synapses. In the
current study, we identify gephyrin as a novel SUMO substrate
and characterize the role of SUMOylation for modulating its
functions in vitro and in vivo. Gephyrin is a cytoplasmic
scaffolding protein that selectively forms postsynaptic scaffolds
at GABAergic and glycinergic synapses, believed to anchor
postsynaptic GABAA receptors (GABAAR) and glycine receptors.
In addition, the transsynaptic adhesion molecule neuroligin-2
might recruit gephyrin to inhibitory synapses via collybistin (CB)
interactions14,15; however, the mechanistic basis underlying this
recruitment process is still unclear. As a multifunctional protein,
gephyrin is subject to extensive PTM by phosphorylation16,
which was shown to be of immediate functional relevance. Thus,
the phosphorylation status of residues S268 and S270 on gephyrin
inﬂuences gephyrin scaffolding properties and thereby directly
impinge on GABAAR synaptic function17,18.
On identifying speciﬁc gephyrin residues that are SUMO1- or
SUMO2-conjugated in vitro and acetylated in vivo, we investi-
gated possible crosstalk between SUMOylation, acetylation and
phosphorylation of gephyrin and assessed the impact on the
formation and size of gephyrin clusters in GABAergic synapses.
Performing in vivo experiments in mice lacking the GABAAR
a2 subunit, we could conﬁrm the signiﬁcance of gephyrin
SUMOylation for its synaptic scaffolding function. Taken
together, this study unravels the critical role for cellular signal
transduction pathways in determining gephyrin SUMOylation,
phosphorylation and acetylation at identiﬁed residues to regulate
its scaffolding properties at speciﬁc postsynaptic sites and in turn
regulating GABAergic function and plasticity.
Results
Gephyrin is a substrate for SUMOylation. SUMO conjugation is
known to either facilitate or prevent inter- and intra-molecular
interactions via conformation changes or direct steric hindrance.
Currently, there are two online tools that are designed to predict
SUMOylation sites in a protein sequence with different levels of
conﬁdence. Screening full-length rat gephyrin sequence in
these online server-based algorithms (http://www.abgent.com/
sumoplot; http://sumosp.biocuckoo.org/) identiﬁed several
potential consensus SUMO motifs in gephyrin (Supplementary
Table 1). To determine whether gephyrin can be SUMOylated, we
expressed and puriﬁed from bacteria full-length STREP-gephyrin
and other essential components for in vitro SUMO reaction, and
performed SUMOylation assays19. Western blot (WB) analysis
showed higher migrating SUMOylated bands of gephyrin,
suggesting that it could be a novel substrate for SUMO1 and
SUMO2 (Fig. 1a). The speciﬁcity of the reaction was established
by excluding either Ubc9 or ATP from the reaction mix.
To validate these results in vivo, we immunoprecipitated (IP)
gephyrin using the antibody 3B11 from C57Bl6/J mouse
whole brain homogenate and performed WB using SUMO1 or
SUMO2 antibodies, conﬁrming gephyrin SUMOylation (Fig. 1b).
We speciﬁcally identiﬁed SUMO1- and SUMO2-conjugated
bands of gephyrin only in 3B11 lane.
The RING domain-containing SUMO E3 ligase PIAS proteins
directly interact with their substrates for SUMOylation. Hence,
we checked for gephyrin interaction with different PIAS family
members. We co-expressed FLAG–gephyrin and myc–PIAS
(1, 2a, 2b, 3) in HEK293 cells, IP’ed gephyrin using anti-FLAG
antibody and performed WB for myc–PIAS. We could observe
interaction between FLAG–gephyrin, and myc–PIAS3 and
myc–PIAS2a (Fig. 1c), suggesting that these two PIAS isoforms
might contribute to gephyrin SUMOylation.
Identiﬁcation of SUMO-conjugated Lys residues in gephyrin.
Unstructured protein domains are preferred sites for phosphor-
ylation, whereas structured domains are preferred sites for
acetylation and SUMOylation20,21. As the central linker domain
of gephyrin is highly unstructured and contains most of the
phosphorylation sites identiﬁed so far, we focused on the
structured G- and E-domains to identify putative SUMO sites.
We screened for surface-exposed Lys residues on G- and
E-domains based on crystal structure data22,23 (Fig. 2a and
Supplementary Table 2). We observed that the majority of
lysine residues are surface exposed on gephyrin. Therefore,
we expressed G- and E-domains as smaller peptide fragments
(80–100 amino acids) with an amino-terminal STREP-tag in
bacteria and performed in vitro SUMO reactions. The ﬁrst assay
with puriﬁed STREP-G domain revealed a strong SUMO1-
conjugated band, but no SUMO2 conjugation (Fig. 2b).
To identify the SUMO1-conjugated residue on G-domain,
we sequentially tested STREP-G1-82, STREP-G40-120 and
STREP-G82-166 peptides for SUMO1 conjugation using
in vitro assay (Supplementary Fig. 1a–c’’). We also mutated
surface-exposed lysine residues in each of the peptides and tested
them for in vitro SUMO1 conjugation. The K148R point
mutation in peptide STREP-G82-166 abolished SUMO1
conjugation (Supplementary Fig. 1c’). To conﬁrm K148 as an
authentic SUMO1 site, we introduced K148R mutation into the
whole length STREP-G domain and performed in vitro SUMO
reaction (Fig. 2c). Mutation of residue K148 abolished G-domain
SUMO1 conjugation.
Similarly, we tested for SUMO1 and SUMO2 conjugation on
the gephyrin E-domain using bacterially puriﬁed STREP-E
domain. In vitro SUMO assays showed both SUMO1 and
SUMO2 conjugation on the gephyrin E domain. To identify
speciﬁc SUMO sites, we tested E domain peptide fragments (wild
type (WT) or mutant) in the in vitro assay (Supplementary
Fig. 1e–h). We identiﬁed K326 and K645 as additional SUMO1
sites on gephyrin E domain. However, we only found one peptide,
STREP-E635-736, with SUMO2 conjugation. Hence, we mutated
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the surface-exposed lysine K724 and conﬁrmed it as a SUMO2
conjugation site (Fig. 2d).
Based on these results, we chose to focus on K148 (SUMO1)
site and K724 (SUMO2) site for detailed characterization. These
two residues are also close to the G-domain dimer and E-domain
trimer interface, making them prabable candidates for gephyrin
scaffold regulation. Hence, we assessed the effects of abolishing
SUMO conjugation of these two residues on inhibitory
neurotransmission by measuring GABAergic mini inhibitory
postsynaptic currents (mIPSC) amplitude and inter-event
intervals. To this end, we co-transfected cultured hippocampal
neurons with eGFP–gephyrin, eGFP–K148R or eGFP–K724R,
along with gephyrin 30-untranslated region (30-UTR) short
hairpin RNA (shRNA)24, to avoid a possible inﬂuence of
endogenous gephyrin on the phenotype of eGFP–gephyrin
SUMO1 and SUMO2 mutants ( Supplementary Fig. 2a–d).
Cells were transfected at 8 DIV and recorded mIPSC from 6 days
later (8þ 6 DIV), using mock-transfected cells as control
(Fig. 2e). Neurons expressing SUMO1-deﬁcient eGFP–K148R
mutant and SUMO2-deﬁcient eGFP–K724R mutant had larger
mIPSC amplitudes and shorter inter-event intervals compared
with WT eGFP–gephyrin (Fig. 2f–g and Supplementary Table 3),
suggesting that preventing gephyrin SUMOylation might enhance
its postsynaptic clustering along with GABAARs and facilitate
GABAergic synaptic transmission. Interestingly, the SUMO2 site
mutant exhibited a more pronounced decrease in mIPSC
inter-event intervals (Supplementary Fig. 2f and Supplementary
Table 3).
The decay kinetics of mIPSCs in neurons transfected
with eGFP–gephyrin, eGFP–K148R or eGFP–K724R were not
signiﬁcantly different (Fig. 2h). It is possible that gephyrin
SUMOylation indiscriminately affects the majority of gephyrin-
containing GABAergic synapses.
PIAS3 inﬂuences gephyrin postsynaptic clustering. We tried to
identify the underlying mechanism for gephyrin SUMOylation
next. Many synaptic proteins have been identiﬁed as SUMO
substrates in vivo25. Hence, we tested whether SUMO1 and
SUMO2 are co-localized with eGFP–gephyrin at GABAergic
postsynaptic sites in primary hippocampal neurons co-transfected
(DIV8) with eGFP–gephyrin and myc–SUMO1 or myc–SUMO2.
We stained for myc and VGAT at DIV15 and analysed for
co-labelling using laser confocal microscopy (Supplementary
Fig. 3a–b’’). We found three distinct subcellular localizations of
myc–SUMO1 and myc–SUMO2 in primary neurons; namely,
only nuclear, only cytosolic and both nuclear and cytosolic.
However, in neurons exhibiting dendritic distribution of
myc–SUMO1 or myc–SUMO2, the staining was co-localized
with eGFP–gephyrin clusters apposed to VGAT-positive
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Figure 1 | Biochemical assay demonstrating gephyrin is a SUMO substrate. (a) In vitro SUMO reaction using puriﬁed proteins show that gephyrin is a
substrate for SUMO-1 and SUMO-2 conjugation, higher migrating gephyrin SUMO bands were detected using Strep-tactin horseradish peroxidase (HRP).
(b) In vivo detection of gephyrin SUMO1 and SUMO2 conjugation. Arrowheads: SUMO modiﬁed gephyrin bands. Higher exposure of the SUMOylated
gephyrin bands is shown below. Lower panel shows loading controls and depletion of gephyrin after IP speciﬁcally in 3B11 lanes (c) FLAG–gephyrin
interaction with myc–PIAS3 and myc–PIAS2a in HEK293 cells.
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Figure 2 | Identiﬁcation and characterization of gephyrin SUMO sites. (a) Cartoon of gephyrin G-domain and E-domain peptide sequences with
identiﬁed surface-exposed lysine residues. The identiﬁed SUMO1 and SUMO2 conjugation sites are marked *. (b) In vitro SUMOylation using bacterial
expressed and puriﬁed STREP-G domain shows SUMO-1 conjugation but not SUMO2 conjugation. (c) In vitro SUMOylation using STREP-G (K148R) mutant
abolishes SUMO-1 conjugation. (d) In vitro SUMO2 reactions using STREP-E (635–736) and STREP-E (635–736) K724R mutant shows SUMO2 conjugation
in the WT peptide but SUMO2 conjugation is completely abolished in the K724R mutant peptide. (e) Sample mIPSC trace measurements in neurons
transfected with eGFP–K148R, eGFP–K724R along with gephyrin 30-UTR shRNA compared with WT or mock transfected neurons. (f) Average mIPSC
amplitude in neurons transfected with eGFP–K148R, eGFP–K724R along with gephyrin 30-UTR shRNA compared with WT or mock-transfected shows
signiﬁcantly increased amplitude. (g) Average mIPSC inter-event interval in neurons transfected with eGFP–K148R and eGFP–K724R along with gephyrin
30-UTR shRNA compared with WT or mock-transfected shows signiﬁcantly reduced inter-event intervals. (h) Decay kinetics of mIPSC currents in WT,
K148R- and K724R-transfected neurons. Images from four independent experimental replicates were analysed; error bars are s.e.m.
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terminals (Supplementary Fig. 3a–b’’, lower panels). Subcellular
localization differences in neurons have not been reported earlier;
we conﬁrmed our observations using speciﬁc antibodies against
endogenous SUMO1 and SUMO2 (Supplementary Fig. 3c–d’).
Similar to myc–SUMO1/2 overexpression, antibody staining for
endogenous SUMO1 and SUMO2 also revealed subcellular
localization differences within the nucleus, soma and dendrites,
suggesting that they are not due to protein overexpression
artefacts.
To inﬂuence gephyrin SUMOylation levels in primary neurons,
we co-expressed myc–PIAS2a or myc–PIAS3 along with
eGFP–gephyrin, as these two PIAS family members speciﬁcally
interact with gephyrin (Fig. 1c). We analysed DIV8þ 7 neurons
co-transfected with PIAS2a or PIAS3 for changes in
eGFP–gephyrin cluster size or density (Fig. 3a–e). Image
quantiﬁcation showed that myc–PIAS2a co-expression does
not change eGFP–gephyrin clustering compared with
eGFP–gephyrin-alone control (Fig. 3d,e). However, neurons
expressing myc–PIAS3 had larger and fewer eGFP–gephyrin
clusters at GABAergic synapses (Fig. 3c, lower panels), as
determined by their apposition to VGAT-positive terminals.
Quantitative analysis (Fig. 3d) showed that myc–PIAS3
co-expression signiﬁcantly increased eGFP–gephyrin cluster
size (0.8±0.04 versus 0.2±0.01 mm2; one-way analysis of
variance (ANOVA) F(2, 1,786)¼ 61.45, Bonferonni post-hoc test,
Po0.0001), while reducing their density (3.2±0.05 per 20mm
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eGFP–gephyrin and myc–PIAS2a or myc–PIAS3 (DIV 8þ 7) shows morphological differences in the presence of myc–PIAS3. (d) Cumulative probability
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dendrite segment versus 6.5±0.6; one-way ANOVA F(2, 48)¼ 4.2,
Bonferonni post-hoc test, Po0.05).
It is well established that substrate speciﬁcity for SUMO
conjugation and de-conjugation is enhanced in the presence of
speciﬁc PIAS family members via their direct interaction with the
substrate. Having identiﬁed K148 and K724 as SUMO1 and
SUMO2 sites on gephyrin, we tested for PIAS3 effect on gephyrin
SUMO mutations. We co-expressed myc–PIAS3 along with
eGFP–K148R or eGFP–K724R in cultured neurons (Fig. 3f,g’).
Analysis at DIV 8þ 7 revealed clear phenotypic differences
between K724R and K148R mutants in the presence of PIAS3
(Fig. 3j–m). Co-expression of myc–PIAS3 with eGFP–K148R
increased the cluster density (5±0.5 versus 3.6±0.2,
Mann–Whitney test, P¼ 0.02; Fig. 3j), whereas not affecting the
cluster size (0.45±0.08 versus 0.36±0.1 mm2, Mann–Whitney
test, P¼ 0.26; Fig. 3k). Conversely, cluster density in neurons
expressing eGFP–K724R and myc–PIAS3 was not altered
(4.2±0.4 versus 5.2±0.5; Mann–Whitney test, P¼ 0.57;
Fig. 3l), but their size was signiﬁcantly increased (0.25±0.01
versus 0.37±0.01 mm2; Mann–Whitney test, Po0.0001; Fig. 3m).
To examine the simultaneous inﬂuence of SUMO1 and
SUMO2 on gephyrin, we generated eGFP–K148R/K724R double
mutant and transfected hippocampal primary neurons in the
presence of gephyrin 30-UTR shRNA (Fig. 3h,h’). Quantitative
analysis showed signiﬁcant increase in eGFP–K148R/K724R
cluster density compared with eGFP–gephyrin (7.6±0.5 versus
5±0.3; one-way ANOVA F(2, 31)¼ 7.8, Bonferonni post-hoc test,
P¼ 0.0017; Fig. 3n), as well as size (0.41±0.01 versus
0.32±0.01 mm2; one-way ANOVA F(2, 1,223)¼ 4.8, Bonferonni
post-hoc test, Po0.0001; Fig. 3o). If K148 and K724 are authentic
SUMO1 and SUMO2 sites that regulate gephyrin scaffolding, the
double mutant eGFP–K148R/K724R should be insensitive to
myc–PIAS3 expression. To test this, we transfected eGFP–K148R/
K724R, gephyrin 30-UTR shRNA and myc–PIAS3 into primary
neurons and analysed for clustering change at DIV 8þ 7
(Fig. 3i,i’). Analysis for cluster density showed no change for
eGFP–K148R/K724R double mutant in the presence or absence
of myc–PIAS3 (Fig. 3n). Interestingly, the cluster size of
eGFP–K148R/K724R in the presence of myc–PIAS3 returned to
WT eGFP–gephyrin baseline levels (0.41±0.01 versus
0.32±0.01, one-way ANOVA F(2, 1,223)¼ 4.8, Bonferonni
post-hoc test, Po0.0001, Fig. 3o). These observations suggested
for additional regulatory mechanism that could inﬂuence PIAS3
SUMO conjugation on gephyrin at K148R and K724R.
PIAS3 gephyrin regulation is phosphorylation dependent.
It has been reported that phosphorylation at S268 by ERK1/2
regulates the size and phosphorylation at S270 by GSK3b
regulates the density of postsynaptic gephyrin clusters17,18. We
wondered whether gephyrin phosphorylation at S268 and S270
would inﬂuence the effect of PIAS3 on gephyrin clustering.
Therefore, we co-transfected myc–PIAS3 and eGFP–S268E
mutant (charged residue mimicking constitutive phosphorylation)
along with gephyrin 30-UTR shRNA and analysed for changes in
eGFP–S268E clustering in DIV 8þ 7 neurons (Fig. 4a,a’).
The co-expression of myc–PIAS3 did not increase the cluster
size of eGFP–S268E mutant, unlike WT eGFP–gephyrin
(Fig. 4b; 0.3±0.01 mm2 versus 0.25±0.01 mm2; one-way ANOVA
F(4,756)¼ 7.5, Po0.0001, Bonferonni post-hoc test, not
signiﬁcant). Hence, phosphorylation status at S268 inﬂuences
PIAS3-dependent changes in gephyrin cluster size. However,
when we compared cluster density, we found that myc–PIAS3
co-expression signiﬁcantly reduced eGFP–S268E cluster density
(3.5±0.5 versus 1.6±0.4; one-way ANOVA F(4,39)¼ 6.5,
P¼ 0.0004; Fig. 4c), similar to PIAS3 effect on WT.
Next, we analysed the possible contribution of S270 phosphor-
ylation status on myc–PIAS3-dependent increase in cluster size
and reduction in cluster density. We analysed DIV 8þ 7 neurons
co-transfected with eGFP–S270E and gephyrin 30-UTR shRNA,
or with eGFP–S270E, myc–PIAS3 and gephyrin 30-UTR shRNA
(Fig. 4d,d’). Quantitative analysis of eGFP–S270E revealed a
signiﬁcant increase in cluster size in the presence of myc–PIAS3
(0.55±0.07 versus 0.32±0.01 mm2; Fig. 4e; one-way ANOVA
F(4,756)¼ 7.5, Po0.0001), conﬁrming that S268 residue is
speciﬁcally involved in regulation of cluster size. Interestingly,
expression of eGFP–S270E did not prevent the myc–PIAS3-
induced reduction in gephyrin cluster density (2.0±0.4 versus
5.5±1.06; one-way ANOVA F(4, 39)¼ 6.5, P¼ 0.0004; Fig. 4f),
indicating that PIAS3 can override the effects of S270
phosphorylation-dependent modulation of gephyrin cluster
density. These results reveal a possible crosstalk between the
PIAS3 and ERK1/2 kinase pathways for gephyrin scaffold size
regulation.
Gephyrin is acetylated at K666. The in vitro SUMO assay using
STREP-G and E domain peptides had suggested the presence of
additional SUMO1 sites on E-domain. In silico analysis of
gephyrin lists K373, K465, K602, K666 and K715 as potential
SUMOylation sites (Supplementary Table 1). Although K373 and
K465 residues are not surface-exposed, we did not ﬁnd K602 to be
an authentic SUMO site (Supplementary Fig. 1f). On the other
hand, residues K666 and K715 are surface-exposed and lie close
to the E-domain dimer interface. Hence, we tested whether K666
and K715 are SUMOylated. For this, we expressed and puriﬁed
STREP-E-domain (wt) and STREP-E containing the K666A,
K715A or K666A/K715A mutations from bacteria to perform
in vitro SUMO1 and SUMO2 reactions as described above
(Fig. 1a). STREP-E (wt) showed both SUMO1 and SUMO2
conjugation (Fig. 5a); however, STREP-E (K666A), STREP-E
(K715A) or STREP-E (K666A/K715A) mutants did not exhibit
any reduction in SUMO-1 or SUMO-2 conjugation (Fig. 5b),
indicating that SUMOylation is unlikely to occur at these two
residues.
Gephyrin can be acetylated at Lys residues (Lys-Ac)16.
Hence, we probed whether either of these two residues that are
strategically located on the E-domain are Lys-Ac. We conﬁrmed
gephyrin Lys-Ac in vivo by gephyrin IP from extracts of either the
cerebral cortex or the cerebellum of adult mice and detection of
Lys-Ac in WB using pan Lys-Ac antibodies and IgG as control.
Gephyrin Lys-Ac band(s) were readily evident only in the
gephyrin lane (Fig. 5c), conﬁrming that gephyrin is acetylated
in vivo. We next tested whether K666 and/or K715 might be
relevant Lys-Ac sites. To determine the speciﬁcity of our assay, we
mutated a nonspeciﬁc Lys residue in the unstructured linker
domain (K219R), as SUMOylation and acetylation are restricted
to structured domains. Whole-cell extracts of HEK293 cells
transfected with FLAG–gephyrin, FLAG–K666A, FLAG–K715A,
FLAG–K219R or FLAG–K666A/K715A were used for gephyrin
IP using anti-FLAG antibody and probed for Lys-Ac in WB using
pan Lys-Ac antibody (Fig. 5d). Lys-Ac bands were readily
detected in lanes containing WT, K715R and K219R gephyrin
mutants, but their intensity was reduced in both K666A and
K666AþK715R gephyrin mutant lanes (Fig. 5d, lanes 3, 5 and 6
versus lanes 4 and 7), suggesting K666 is a major acetylation site
on gephyrin. To ensure equal IP of gephyrin in all the lanes, we
stripped the blot and re-probed using anti-gephyrin antibody
3B11 (Fig. 5d, lower lanes).
Next, we investigated the importance of K666 acetylation for
gephyrin postsynaptic clustering. We transfected neurons with
eGFP–K666Q (Ac mimicking) or eGFP–K666A (Ac lacking)
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mutants along with 30-UTR gephyrin shRNA and performed
cluster analysis at DIV 8þ 7 relative to eGFP–gephyrin control
(Fig. 5e–g’). Quantiﬁcation of cluster density (5.1±0.57 versus
4.1±0.41 and 4.3±0.47, one-way ANOVA F(2, 27)¼ 2.3, P¼ 0.1)
showed no signiﬁcant differences. Comparison of cluster size
(0.28±0.01 versus 0.4±0.01 mm2 and 0.34±0.01 mm2; one-way
ANOVA F(2, 604)¼ 11.4, Po0.0001; Bonferonni post-hoc test)
revealed signiﬁcant differences when K666 contains the acetyla-
tion mimicking mutation compared with WT control (Fig. 6g,h).
Gephyrin acetylation inﬂuences PIAS3 effect. SUMOylation has
been shown to be sometimes dependent on phosphorylation
status of the substrate8. We wanted to test whether a link between
acetylation and SUMOylation also exists. Hence, we co-
transfected primary neurons with myc–PIAS3 and eGFP–
K666A or eGFP–K666Q (acetylation mimicking), to evaluate
whether the acetylation status at K666 might inﬂuence PIAS3
effect on gephyrin clustering (Fig. 6a–c’). Quantitative analysis
revealed a signiﬁcantly decreased eGFP–K666A cluster density
(6.5±0.9 versus 3.8±0.4; Mann–Whitney test, P¼ 0.003;
Fig. 6d), but no change in cluster size (0.29 versus 0.24 mm2;
Mann–Whitney test, P¼ 0.6; Fig. 6e). On the other hand,
acetylation mimicking K666Q mutation completely blocked all
myc–PIAS3-induced changes in cluster size and density
(Fig. 6f,g). This observation suggests that the acetylation status
at K666 might inﬂuence PIAS3-dependent gephyrin SUMOylation.
Protein phosphorylation-dependent acetylation has been
reported21. We thus determined whether acetylation of
gephyrin at K666 might be coupled to phosphorylation at S268
site by generating eGFP–S268A/K666A and eGFP–S268E/K666A
double mutants, and analysing their clustering in DIV 8þ 7
neurons (in the presence of gephyrin 30-UTR shRNA; Fig. 6h–j’).
Interestingly, eGFP–K666A/S268A combination mutation signiﬁ-
cantly reduced the cluster size compared with eGFP–K666A
(0.32±0.01 versus 0.28±0.01; one-way ANOVA F(4, 692)¼ 5.6,
P¼ 0.0037; Bonferonni post-hoc test; Fig. 6k); however,
eGFP–S268E/K666A mutation had cluster size similar to
eGFP–gephyrin control (Fig. 6j,j’). However, quantiﬁcation for
postsynaptic cluster densities of eGFP–gephyrin, eGFP–S268A/
K666A, eGFP–S268E/K666A and eGFP–K666A did not exhibit
signiﬁcant differences (Fig. 6l; one-way ANOVA F(4, 27)¼ 0.0024,
P¼ 0.9).
We wondered whether the PIAS3-induced change in cluster
size and density (Fig. 3) could be blocked by eGFP–S268E/K666A
 eGFP-S270E
3′UTR shRNA
a a′
3′UTR shRNA 3′UTR shRNA
eGFP-S268E 
d d′
eGFP-S270E+PIAS3
3′UTR shRNA
0%
20%
40%
60%
80%
100%
2 4 6
Cluster density per 20 μm dendrite
Gephyrin
S268E 
Gephyrin + PIAS3
0%
20%
40%
60%
80%
100%
0.
03
0.
15
0.
27
0.
39
0.
51
0.
63
0.
75
0.
87
0.
99 1.
1
2.
3
S270E
S270E + PIAS3
Gephyrin + PIAS3
0%
20%
40%
60%
80%
100%
2 4 6 8 10
S270E
S270E + PIAS3
Gephyrin + PIAS3
0%
20%
40%
60%
80%
100%
0.
03
0.
15
0.
27
0.
39
0.
51
0.
63
0.
75
0.
87
0.
99 1.
1
2.
3
S268E
S268E + PIAS3
Gephyrin + PIAS3
Gephyrin 
8 10
S268E + PIAS3
Cluster size in μm2
Gephyrin
Gephyrin 
Cluster density per 20 μm dendrite
Cluster size in μm2
eGFP-S268E+PIAS3 
f
Cu
m
ul
at
ive
 p
ro
ba
bi
lity
 (%
)
D
en
dr
ite
s 
(%
)
D
en
dr
ite
s 
(%
)
Cu
m
ul
at
ive
pr
ob
ab
ilit
y 
(%
)
***
***
***
e
b c
Figure 4 | Morphology of ERK1/2 phosphorylation mimicking eGFP–S268E gephyrin mutant in neurons co-transfected with myc–PIAS3 (DIV 8þ 7).
(a,b) Cumulative probability distribution of eGFP clusters in the presence of myc–PIAS3 shows that phosphorylation at S268 blocks PIAS3-mediated cluster
growth. (c) Synaptic cluster density distribution in neurons co-expressing myc–PIAS3 shows that gephyrin phosphorylation at S268 cannot prevent
PIAS3-mediated reduction in cluster density. (d,d’) Morphology of GSK3b phosphorylation mimicking eGFP–S270E gephyrin mutant in neurons
co-transfected with myc–PIAS3 (DIV 8þ 7). (e) Cumulative probability distribution of eGFP clusters in neurons expressing myc–PIAS3 shows that
phosphorylation at S270 does not block PIAS3-mediated size growth. (f) Synaptic cluster density distribution in neurons co-transfected with myc–PIAS3
shows signiﬁcant reduction compared to eGFP–S270E alone control cells. Scale bar, 5 mm. Images from three independent experimental replicates were
analysed; error bars are s.e.m.
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mutation. We co-expressed myc–PIAS3, eGFP–S268E/K666A
and gephyrin 30-UTR shRNA in hippocampal neurons and found
that eGFP–S268E/K666A mutation blocked all effect of PIAS3 on
gephyrin cluster size and density change (Fig. 6m,n). These
results reveal the importance of K666 and S268 sites for PIAS3
action on gephyrin. In conclusion, these experiments suggest that
in addition to SUMO1 and SUMO2 modiﬁcations at K148 and
K724, respectively, acetylation at K666 and phosphorylation at
S268 are also important determinants of gephyrin-clustering
properties.
Our data point towards a convergence of signalling cascades to
regulate gephyrin scaffolding at GABAergic postsynaptic sites.
However, it is unclear whether gephyrin cluster formation is a
prerequisite for GABAergic synapse function. To test this
principle, we generated eGFP–gephyrin dominant-negative
(DN) mutant by introducing a premature stop codon after
the K666 residue. This eGFP–gephyrin DN mutant exhibits a
diffuse, non-clustered distribution in primary hippocampal
neurons (Supplementary Fig. 4a). We examined the functional
consequences of gephyrin scaffold disruption on GABAergic
STREP-E
(WT)
STREP-E
(K715A)
STREP-E
(K666A)
STREP-E
(K715A+K666A)
50 kDa
65 kDa
80 kDa
WB 3B11
SUMO1
SUMO2
ATP
++
++
++– –
–
– –
–
++
++
++– –
–
– –
–
++
++
++– –
–
– –
–
++
++
++– –
–
– –
–
WB 3B11
Unmodified 
STREP-E
SUMO- 
modified 
substrate
Ubc9 +++ + +++ + +++ + +++ +
WT WT K6
66
A
K7
15
A
K2
19
R
K6
66
A+
K7
15
A
WB: Pan Ac K
IP Ab: IgG Gephyrin 3B11
WB: 3B11IP Ab: IgG 3B11
Co
rte
x
Ce
reb
ellu
m
Wh
ole
 br
ain
WB: Pan Ac K
95 kDa
95 kDa
95 kDa
eGFP-gephyrin eGFP-K666AvGAT
Ac gephyrin 
Ac gephyrin 
Gephyrin 
eGFP-K666AeGFP-gephyrin 
vGAT
3′ UTR shRNA 3′ UTR shRNA
c d
e
e′
f
f′
Cluster density per
20 μm dendrite 
Gephyrin+shRNA 3′UTR
K666Q+shRNA 3′UTR
Cluster size in μm2
h
Ac gephyrin 
Ac gephyrin 
0
2
6
4
K666A+shRNA 3′UTR
0.0
0.1
0.2
0.3
0.4
0.5
***
*
g
g′
i
eGFP-K666Q vGAT
3′ UTR shRNA
eGFP-K666Q
a b
Figure 5 | K666 is a novel acetylation site on gephyrin. (a) In vitro SUMO reaction to using bacterial expressed and puriﬁed STREP-E domain shows both
SUMO1 and SUMO2 conjugation at the carboxy terminus. (b) In vitro SUMO reaction using consensus site mutants K666A, K715A and K666AþK715A
shows SUMOylation. (c) In vivo analysis after denaturing IP for gephyrin and WB for Pan Lys-Ac residue shows that gephyrin is acetylated in vivo.
(d) Acetylation assay using FLAG–gephyrin, K666A, K715A, K219R or K666AþK715A site mutants in HEK293 cells. Denaturing IP for FLAG–gephyrin
followed by WB against Pan Lys-Ac residue shows loss of acetylation in K666A and K666AþK715A mutants. Gephyrin levels after IP was determined by
stripping the blot and WB using 3B11 antibody (lower panel). (e–g’) Morphology of eGFP–K666A and eGFP–K666Q mutants in primary hippocampal
neurons compared with WT gephyrin. (h) Synaptic cluster density show similar distribution for eGFP–K666A and eGFP–K666Q compared with
eGFP–gephyrin. (i) Mean size of eGFP–gephyrin and eGFP–K666A mutant is similar, but eGFP–K666Q has a signiﬁcantly higher cluster size. Scale bar,
5 mm. Images from atleast four independent experimental replicates were analysed; error bars are s.e.m.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13365
8 NATURE COMMUNICATIONS | 7:13365 | DOI: 10.1038/ncomms13365 | www.nature.com/naturecommunications
transmission, by recording GABAergic mIPSCs in neurons
co-expressing eGFP–gephyrin DN and gephyrin 30-UTR shRNA
at either DIV 8þ 6 or DIV 11þ 5 (Supplementary Fig. 4b and
Supplementary Table 3). Mock-transfected and eGFP–gephyrin
control cells exhibited similar mIPSC amplitudes and inter-event
intervals (Supplementary Fig. 4c,d). However, neurons expressing
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eGFP–gephyrin DN mutant showed signiﬁcantly reduced mIPSC
amplitudes and prolonged inter-event intervals (Supplementary
Fig. 4c–f). Furthermore, the decay time constants of these events
were also signiﬁcantly longer compared with those measured in
eGFP–gephyrin-transfected neurons (Supplementary Fig. 4g,h),
suggesting that disruption of gephyrin scaffold might mainly
affect either proximal synapses and/or speciﬁc subpopulation of
GABAARs. Therefore, we morphologically tested for changes in
the synaptic expression of GABAARs in eGFP–gephyrin or
eGFP–gephyrin DN-expressing neurons. Although we could
detect a2 subunit containing GABAARs in eGFP–gephyrin-
transfected neurons, we saw a clear deﬁcit in a2 and g2 subunits
in eGFP–K666A/S268E neurons (Supplementary Fig 4i–k, lower
panels arrow heads). These results suggest that gephyrin
scaffolding is essential for the surface expression of a2 subunit
containing GABAARs.
Cellular signalling pathways crosstalk. So far, our results show a
morphological correlation between SUMO, acetylation or phos-
phorylation pathway(s). Hence, to obtain more direct evidence we
performed proximity ligation assay (PLA) in primary hippo-
campal neurons transfected with eGFP–gephyrin. PLA allows for
protein modiﬁcation and/or interactions to be detected with high
sensitivity and single-molecule resolution.
Testing for direct SUMO1 or SUMO2 conjugation on
eGFP–gephyrin conﬁrmed our biochemical data. Furthermore,
we could also conﬁrm the direct inﬂuence of PIAS3 on gephyrin
SUMO1 and SUMO2 conjugation using this assay (Fig. 7a).
Consistent with our biochemical and morphological evidence,
co-expression of His-PIAS3 showed a signiﬁcant increase in
SUMO1 and SUMO2 conjugation on eGFP–gephyrin (Fig. 7a,
right panel; Student t-test, P¼ 0.0008). Our data suggests a
link between gephyrin phosphorylation at S268 residue and
SUMOylation at K148 and K724 residues. To conﬁrm the
crosstalk between phosphorylation and SUMOylation pathways,
we performed PLA using eGFP–gephyrin, eGFP–S268A
or eGFP–K148R/K724R mutation and myc–SUMO1 or
myc–SUMO2. Consistent with our other results, both
eGFP–S268A and eGFP–148R/K724R mutations signiﬁcantly
reduce SUMO1 and SUMO2 conjugation on gephyrin (Fig. 7b;
one-way ANOVA, P¼ 0.0028).
Our results also predict a direct crosstalk between SUMO
pathway and gephyrin acetylation. To conﬁrm this we performed
PLA using antibodies against enhanced green ﬂuorescent protein
(eGFP) and Ac-Lys residue. Although we could detect a strong
Ac-Lys conjugation on WT eGFP–gephyrin control, we saw a
signiﬁcantly reduced Ac-Lys signal on our SUMO mutant
eGFP–K148R/K724R (Fig. 7c, Student t-test, Po0.0001).
To conﬁrm direct convergence of SUMO, ERK1/2 and
acetylation pathways on gephyrin, we either used the
eGFP–S268A mutation or pharmacological blockers for the
ERK1/2 pathway (PD98059; 25 mM, 14 h) or SUMO pathway
(2-D08; 50 mM, 14 h). Endogenous Ac-Lys conjugation on
eGFP–S268A was signiﬁcantly reduced. Furthermore, pharmaco-
logical blockade of ERK1/2 or SUMO pathways also reduced
Ac-Lys conjugation on eGFP–gephyrin (Fig. 7d, one-way
ANOVA, P¼ 0.001). These results offer proof for the conver-
gence of multiple signalling pathways on gephyrin scaffold, to
regulate its clustering properties.
Next we used biochemistry to further conﬁrm the link between
phosphorylation, SUMOylation and acetylation pathways on
gephyrin. For this we transfected eGFP–gephyrin, eGFP–K148R,
eGFP–K724R, eGFP–K666A, eGFP–K666Q or eGFP–K148R/
K724R into HEK293 cells and performed WB analysis using a
gephyrin S270 phospho-speciﬁc antibody. Our analysis
shows elevated levels of phospho-S270 in K724R (SUMO2)
site mutation and signiﬁcantly reduced phospho-S270 in
K148R/K724R mutation (Supplementary Fig. 5). We also tested
the interdependence of gephyrin phosphorylation on PIAS3
interaction. For this we co-transfected HEK293 cells with
myc–PIAS3 and FLAG–gephyrin, FLAG–S268A, FLAG–S268E,
FLAG–S270A or FLAG–S270E, followed by IP for myc–PIAS3
and WB against FLAG (Supplementary Fig. 5). Consistent with
our PLA results we found a weaker interaction between PIAS3
and S268A mutation compared with WT; on the other hand,
S270 site mutants bound better to myc–PIAS3 compared with
S268 mutants or WT gephyrin. These biochemical observation is
consistent with our morphology data showing eGFP–S270E but
not eGFP–S268E mutant cluster size is inﬂuenced by PIAS3
(Fig. 4b,e).
Pharmacological intervention and transgenic rescue in vivo.
Results so far add to the evidence that gephyrin is heavily,
posttranslationally modiﬁed16 and the functional relevance
for multiple PTMs on gephyrin remains unclear. If
SUMOylation acts upstream of the phosphorylation and
acetylation pathways, then gephyrin SUMO conjugation can
be the rate-limiting step for scaffolding at GABAergic synapses.
Hence, blocking the SUMO pathway in neurons where
gephyrin scaffolding is disrupted should rescue scaffolding
at GABAergic synapses. We have reported earlier that
GABAAR a2 subunit-deﬁcient mice exhibit a profound loss of
gephyrin clustering in CA1 pyramidal cells26. The lead cause
for this observed gephyrin scaffold loss is not known; therefore,
we tested for transcriptional defects in gephyrin and CB,
a RhoGEF important for gephyrin clustering and GABAergic
synapse function27,28 in Gabra2 knockout (KO) mice.
We performed quantitative real-time PCR analysis from
WT and a2 / mice brain tissue, and did not observe
any signiﬁcant differences in the transcript levels of gephyrin
and CB (Fig. 8a), suggesting that loss of gephyrin clustering in
a2 / mice is not due to reduced gephyrin transcription. Next,
we assessed for gephyrin and CB protein levels using brain
homogenates from WT and a2 / mice. We found 10%
reduction in gephyrin protein in the absence of Gabra2 gene;
interestingly, we also found a 60% reduction in CB protein in
a2 / mice (Fig. 8b).
The 10% loss of gephyrin protein in a2 / could not be a
signiﬁcant cause for the observed scaffolding loss. Hence, we
wondered whether gephyrin PTM was adversely affected in the
absence of functional a2 GABAARs at synaptic sites. We
examined for difference in gephyrin SUMOylation between WT
and a2 / mice. IP for gephyrin and WB for SUMO1 or
SUMO2 consistently revealed stronger gephyrin SUMO1- and
SUMO2-conjugated bands in Gabra2 KO samples compared with
WT control (Fig. 8c,d).
If enhanced gephyrin SUMOylation is indeed the main
factor contributing to the scaffolding loss at GABAergic
terminals, then pharmacological blockade of the SUMO
pathway in a2 / cells should restore gephyrin scaffolding.
We stereotactically injected SUMO pathway inhibitor 2-D08
(30 mM) or saline into a2 / mice (n¼ 3) on one hemi-
sphere near the hippocampal area. Twenty-four after injection,
we analysed for gephyrin and g2 GABAAR clusters in both
ipsi- and contralateral hemispheres. One could see inﬂamma-
tion using antibody against CD68, a marker for microglia, near
the lesion caused by the 2-D08 injection, but not saline. We
imaged away from the lesion area to avoid tissue auto-
ﬂuorescence and nonspeciﬁc antibody reactivity. Quantiﬁcation
for gephyrin and g2 GABAARs co-clustering showed a
signiﬁcant increase in density at the ipsi-lateral hemisphere
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in comparison with the contra-lateral control area (Student
t-test, P¼ 0.0025; Fig. 8e,e’, right panel). The rescue of
gephyrin scaffolding by blocking the SUMO pathway offers
evidence for gephyrin SUMOylation to act upstream of the
phosphorylation and acetylation pathways.
To obtain a more direct evidence for gephyrin scaffold
recruitment downstream of a2 GABAARs via the modulation of
SUMO pathway, we in utero co-electroporated LoxP-stop-LoxP-
eGFP-gephyrin, LoxP-stop-LoxP-eGFP-K148R or LoxP-stop-
LoxP-eGFP-K724R, along with tdTomato and ERT-Cre-ERT
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into E14 embryos of a2 / mice. We induced the expression of
the gephyrin constructs at P20 using tamoxifen (4-OHT) and
performed histological analysis at P30. Focusing on transfected
neurons in layers 2 and 3 of parietal cortex, we observed in
a2 / mice that neurons transfected with eGFP–gephyrin had a
diffuse eGFP staining with only 2 to 3 clusters (Fig. 8f). However,
a2 / neurons transfected with either of the SUMO mutants
eGFP–K148R or eGFP–K724R showed distinct gephyrin cluster-
ing (Fig. 8g,h). The successful rescue of gephyrin clustering
in vivo using either single point mutation of SUMO1 or SUMO2
site demonstrates that SUMO pathway converges onto
gephyrin upstream of the phosphorylation and acetylation
pathways. Furthermore, it also shows the speciﬁcity of our
identiﬁed K148 and K724 residues for gephyrin scaffold
regulation in neurons.
Discussion
Scaffolding molecules in the postsynaptic density of glutamatergic
synapses have canonical PDZ domains mediating multiple
protein–protein interactions. However, gephyrin and its main
interaction partners lack such an interaction domain, indicating
that protein scaffolds at inhibitory synapses rely on distinct
regulation mechanisms. A current view posits that a multi-
molecular complex at inhibitory synapses is assembled via
gephyrin self-aggregation. However, such a model fails to explain
why gephyrin oligomerization does not occur nonspeciﬁcally and
provides little insights into its regulation.
In this study, we demonstrate how crosstalk between three
different PTMs, SUMOylation, acetylation and phosphorylation
mediates gephyrin clustering speciﬁcally at GABAergic post-
synaptic sites (see model, Fig. 9). We posit that SUMOylation acts
upstream of acetylation and phosphorylation. The formation of
postsynaptic clusters is facilitated by de-conjugation of SUMO1 at
K148 and SUMO2 at K724. Successful de-SUMOylation
(presumably by members of the SENP protein family) leads to
deacetylation at K666 and dephosphorylation at S268 residues to
promote clustering. Furthermore, by identifying speciﬁc residues
in gephyrin that inﬂuence its cluster size and density, we also
posit that phosphorylation at S268 and deacetylation at K666
renders SUMOylation sites K148 and K724 ineffective in
inﬂuencing gephyrin oligomerization. Quantitative analysis of
gephyrin molecules using super-resolution microscopy showed
that inhibitory postsynapse (PSD) comprises of 3,000–10,000
gephyrin molecules29. This study also identiﬁed micro-aggregates
of gephyrin that are rapidly recruited to inhibitory postsynaptic
sites for scaffold formation. Our study offers a model (Fig. 9)
illustrating how SUMOylation, acetylation and phosphorylation
act to recruit gephyrin molecules, to promote scaffolding based
on the synapse requirement. By drawing on the importance of
gephyrin phosphorylation at Ser270 and Ser268 residues to
regulate cluster density and size17,18, the current study takes this
understanding further by showing how PIAS3-mediated gephyrin
SUMOylation could be dependent on S268 phosphorylation and
K666 acetylation status (Supplementary Fig. 5). The importance
of gephyrin acetylation has not been understood so far; our data
demonstrates the central role of K666 acetylation for gephyrin
SUMO conjugation and micro-cluster maintenance.
Although multiple GABAAR subunits have been shown to
interact with gephyrin, it has become increasingly clear that
gephyrin-independent GABAAR localization and clustering at
synapses can occur. On the other hand, gephyrin itself depends
on synaptic GABAARs to form postsynaptic clusters at inhibitory
synapses in a neuronal cell-speciﬁc mechanism16. In Gabra2 /
mice speciﬁc loss of gephyrin from CA1 pyramidal cells, but
normal expression and function of a1 GABAAR, has been
reported, suggesting that the a2 subunit has a fundamental
inﬂuence on recruiting gephyrin at postsynaptic sites26.
In the current study, we rescue gephyrin clustering in
Gabra2 / mice using both pharmacological blocker of SUMO
and SUMOylation-defective gephyrin mutants, to demonstrate
that modulation of this speciﬁc gephyrin PTM facilitates
scaffolding at GABAergic postsynaptic sites. Further studies are
required to uncover the molecular link between a2 GABAARs and
gephyrin de-SUMOylation. It has been reported that neuroligin-2
KO also leads to gephyrin cluster and GABAergic synapse loss
from perisomatic region of neurons14. It is still unclear what
proportion of neuroligin-2-containing synapses also contain a2
GABAARs, especially given that in Gabra2 KO mice we also see
gephyrin cluster loss in the stratum radiatum of CA1. The
signiﬁcance of gephyrin PTMs for regulating GABAergic
transmission is supported by another independent study
showing gephyrin dephosphorylation at S270 residue regulates
dendrite growth and branching by altering GABAergic, but not
glutamatergic transmission30.
Our current study identiﬁes SUMO1 and SUMO2 co-localized
with gephyrin clusters at GABAergic synapses. We observed three
distinct subcellular distributions of SUMO1/2 proteins in
neurons. When SUMO proteins were enriched in dendrites, we
observed co-localization with eGFP–gephyrin at VGAT-positive
terminals (Supplementary Fig 3a–b’’). It is possible that speciﬁc
cellular signal(s) regulate SUMO subcellular localization within
neurons, thus contributing to differences in synaptic responses
within a given network. However, the exact nature of such a
signalling factor is currently unclear.
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Figure 9 | Model for gephyrin scaffolding at GABAergic synapses. Crosstalk between acetylation, phosphorylation and SUMOylation pathways
regulate gephyrin scaffold formation at GABAergic postsynaptic sites.
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In the current study we also identiﬁed additional SUMO1
conjugation sites on gephyrin E domain. It is likely to be that
more than one site is SUMO2 conjugated on gephyrin, opening
up possibilities for diverse regulatory effects of SUMO on
gephyrin subcellular localization and function. In addition, our
data highlight a currently unknown role for GABAARs in
inﬂuencing gephyrin SUMO conjugation for scaffold recruitment
and synapse function.
Identiﬁcation of diverse gephyrin-interacting molecules and
their role in gephyrin clustering led to at least two different
models, both implicating CB and emphasizing the need of speciﬁc
GABAARs subunits for scaffold formation16. In addition,
GABAAR PTM is known to play an important role in
regulating GABAergic synapse function and plasticity.
Phosphorylation of speciﬁc receptor subunits has been shown
to inﬂuence surface trafﬁcking, lateral diffusion to and from
synaptic sites along the plasma membrane, and receptor
internalization31–33. It is rather unlikely, in our view, that
changes in gephyrin-scaffolding properties and receptor
trafﬁcking/function via PTMs are mutually exclusive. Rather,
we propose that speciﬁc currently unknown neurotrophic
factor(s) signal downstream to recruit speciﬁc kinases,
phosphatases, acetyl-transferase and so on to inhibitory
postsynaptic sites, to inﬂuence GABAergic synaptic plasticity by
acting in concert on the gephyrin scaffold and the receptors
anchored to it.
Finally, gephyrin PTM-dependent scaffolding dynamics could
act as a signalling hub integrating heterosynaptic activity, to
adjust the strength of GABAergic transmission. We have recently
reported that NMDA (N-methyl-D-aspartate) receptor-dependent
neuronal depolarization regulates gephyrin phosphorylation
in a CaMKII-dependent mechanism, to upregulate perisomatic
inhibition and facilitate neuronal homeostasis34. Experimentally,
mutations in GABAAR subunit genes that indirectly
affect postsynaptic gephyrin clustering have been used to
generate models for neurodevelopmental and neuropsychiatric
disorders35,36. In light of our data demonstrating the importance
of gephyrin scaffolding, these perturbations at the receptor levels
could induce alterations in neuronal network by the disruption of
gephyrin signalling hubs at inhibitory postsynaptic sites.
Methods
Bacterial expression vectors. IBA7-STREP-gephyrinP1, IBA7-STREP-E-domain
and IBA7-STREP-G-domain have been described before17. pGEX-E1, pET28a-
His-Ubc9, pET28a-His-SUMO1GG and pET28aHis-SUMO2GG are described
earlier37. IBA7-STREP (K666A, K715A) and IBA7-STREP-K715AþK666A were
created in a eGFP–gephyrin P1 template using site-directed mutagenesis PCR,
following the manufacturer’s instructions (Stratagene) and the mutations were
sequence conﬁrmed. Gephyrin sequence was subcloned into IBA7 vector using
EcoRI and KpnI sites. IBA7-STREP-G peptides (1–82, 83–166 and 40–120) and
IBA7-STREP-E peptides (326–454, 455–558, 559–634, 635–736) were generated by
PCR ampliﬁcation using eGFP–gephyrinP1 as template and subcloned into IBA7
vector using EcoRI and KpnI sites. Numbering refer to the amino acid number in
the rat gephyrin-P1 complementary DNA (NCBI Reference Sequence: NP
074056.2). IBA7-STREP-G1-82 (K67N, K57R), IBA7-STREP-G40-120 (K77R,
K101R), IBA7-STREP-G83-166 (K148R) and IBA7-STREP-G K148R mutants were
created by site-directed mutagenesis PCR using respective WT template and the
mutations were sequence conﬁrmed. Similarly, IBA7-E326-454, IBA7-E455-558,
IBA7-E559-634 and IBA7-E635-736 were also generated by PCR ampliﬁcation
using eGFPC2–gephyrin as template and subcloning the PCR fragment into IBA7
vector using EcoRI and KpnI sites. IBA7-E326-454 (K328R, K362R and K373R),
IBA7-E455-558 (K497R, K521R and K473R) and IBA7-E635-736 (K724R
and K645R) were generated using site-directed mutagenesis and sequence
conﬁrmed.
Neuronal expression vectors. eGFP–Gephyrin P1 has been described before17.
pCR-HA-SUMO1 and pCR-HA-SUMO2 are described in ref. 38; pCDNA3–myc
SUMO1/2, pCI-His-PIAS3 and pCMV-6xmyc-PIAS2b have been described
earlier37. pmU6Pro-gephyrin shRNA (30-UTR and 30-UTR-3m) have been
described earlier17,24. eGFP (gephyrin, S268A, S268E, S270A and S270E) have been
described earlier17,18. eGFP–GephyrinP1 K148R, K724R, K148R/K724R, K666A,
K666Q, S268A/K666A, S268E/K666A were obtained from eGFP–GephyrinP1
template by site-directed mutagenesis PCR and sequence conﬁrmed.
pCAG-ERT2Cre tamoxifen-inducible Cre recombinase has been described
earlier39. pCAG-LoxP-Stop-LoxP-GFP-Gephyrin has been described earlier39.
pCAG-LoxP-Stop-LoxP-GFP-K148R and pCAG-LoxP-Stop-LoxP-GFP-K724R
were created by subcloning into pCAG-LoxP-Stop-LoxP-GFP-Gephyrin plasmid
after removing GFP–gephyrin using NheI and KpnI, and sequence conﬁrmed.
Antibodies. The antbodies used are as follows: rabbit anti-STREP horseradish
peroxidase (1:10,000, BioRad, 161-0380), Mouse anti-Gephyrin 3B11 (1:1,000,
SySy, 147111), mouse anti-gephyrin mAb7a (1:2,000, SySy, 147021), rabbit
anti-vGAT (1:3,000, SySy, 131003), mouse anti-vGAT (1:5,000, SySy, 131011),
rat anti-HA (1:3,000, Roche), mouse anti-Myc (1:5,000, Roche, 11667149001),
mouse anti-FLAG (1:5,000, Sigma-Aldrich, F3165), rabbit anti-GFP (1:5,000,
Synaptic Systems, 132002), chicken anti-GFP (1:5,000, Chemicon, AB16901),
mouse anti SUMO-1 (1:1,000, 21C7, Hybridoma bank), mouse anti SUMO2/3
(1:1,000, 8A2, Hybridoma Bank), rabbit anti-SUMO1 (1:250, Epitomics, 1563-1),
rabbit anti-SUMO2/3 (1,250, Epitomics, 2970-1), rabbit anti pan-Acetylated Lysine
antibody (1:1,000, Cell Signaling, 9441) and mouse anti-Ac-Lysine (AKL5C1)
(1:2,000, Santa Cruz, Sc32268). Gephyrin anti-S270 phospho-antibody has been
described earlier28. The following secondary antibodies were used: goat anti-mouse
IgG Cy3 (1:500, Jackson Immunoresearch, 115165), goat anti-mouse IgG Cy5
(1:500, Jackson Immunoresearch, 115175), goat anti-rabbit IgG Cy3 (1:500,
Jackson Immunoresearch, 111165), goat anti-rabbit IgG Cy5 (1:500, Jackson
Immunoresearch, 111175), goat anti-mouse IgG alkaline phosphatase (AP)
(1:30,000, Sigma-Aldrich, A3562) and goat anti-rabbit IgG AP (1:30,000,
Sigma-Aldrich, A3687).
Cell lines and transfection. HEK293T cells (ATCC, CRL 11268) tested negative
for mycoplasma and were cultured at 37 C, 5% CO2 in DMEM medium
supplemented with 5% fetal bovine serum and were transfected with 3–6 mg
DNA 14 h postplating using polyethylenimine (Polyscienes, Inc.) according to the
manufacturer’s recommendation. The cells were lysed 12–24 h post transfection for
analysis.
IP and WB analysis. Brain homogenates were prepared as described earlier17.
IP analysis was performed using (1–2 mg) antibodies and the protein complexes
were collected using 30ml protein G agarose beads. The bound complexes were
washed in high-salt buffer and twice in EBC buffer (50mM Tris pH 8.0, sodium
chloride 120mM and NP-40 0.5%). Washed beads were boiled 5min, 90C in 2
Simple Buffer (SDS and 15% b-mercaptoethanol) and using SDS–PAGE at 140V,
room temperature (RT). Proteins were transferred on a polyvinylidene ﬂuoride
membrane (37V, 90min), blocked in 5% western blocking reagent (Roche
Diagnostic) for 10min and incubated 1 h with primary antibody solution.
Membrane was washed three times in 1TBST (50mM Tris-HCl, 150mM NaCl
and 0.05% Tween-20) and incubated with secondary antibody linked to AP or
horseradish peroxidase, to allow visualization of the protein bands.
Bacterial overexpression of proteins and puriﬁcation. Bacteria (BL21; pLyss)
expressing the appropriate plasmid of interest were grown in 500ml of media to
OD600¼ 0.6. Protein expression was induced using 1mM anhydrotetracycline or
1mM isopropyl-b-D-thiogalactoside for 4 h, 30 C and pelleted (11,000 r.p.m.,
20min). Bacterial pellet was lysed in EBC lysis buffer containing cOmplete
mini protease inhibitor cocktail (Roche Diagnostic) and 2mgml 1 lysozyme
(AppliChem, A37110001). Bacterial cells were broken by sonication (ten cycles of
30 s each). The clear cell lysate was collected by centrifugation (18,000 r.p.m.,
30min, 4 C) and proteins puriﬁed using FPLC (Amersham) system, immobilized
metal ion afﬁnity chromatography.
Bacteria expressing pGEX-SAE1/2 plasmid were induced with isopropyl-b-D-
thiogalactoside and lysed using the lysis buffer: 50mM NaH2PO4 pH 8, 300mM
NaCl, 10% glycerol, 0.5% Tween-20, 5mM dithiothreitol (DTT), cOmplete mini
protease inhibitor cocktail (Roche Diagnostic) and 2.5mM imidazole. This
contained a His-tag, a GST-tag and a thrombin cleavage site, and was puriﬁed
using the NiNTA column and Glutathione Sepharose column using FPLC as
described in the manufacturer’s instructions (GE Healthcare). Elution was done
using 10CV elution buffer: 50mM NaH2PO4 pH 8, 300mM NaCl, 10% glycerol,
0.5% Tween-20, 5mM DTT and 250mM imidazole, collected fractions were
dialysed again with PBS pH 7.4, 0.1% Triton X-100 and 5% glycerol, and incubated
on 2ml GST-Sepharose (GE healthcare) for 1 h, 4 C, rotor. Bead were washed
twice in PBS and 25 cleavage unit of thrombin (GE Healthcare) were applied to a
total volume of 1.5ml PBS and incubated overnight at 37 C on the rotor. Cleaved
fraction was puriﬁed using 2ml Ni-Sepharose bead volume, washed, eluted and
dialysed using the same protocol as in the ﬁrst run of puriﬁcation. Aliquots were
stored at  80 C. Puriﬁed proteins were examined for purity and expression levels
using Coommasie staining of SDS gel.
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In vitro SUMOylation assay. STREP-gephyrin, STREP-G, STREP-E or
STREP-gephyrin peptides were immobilized using Strep-tactin sepharose beads
(IBA GmbH, 40 ml per 100 ml lysate) for 30min, batch puriﬁed using EBC buffer
and equilibrated in SUMO buffer (50mM Tris-HCl pH 8, 50mM NaCl, 5mM
MgCl2, 10% glycerol and 0.5mM DTT) before in vitro SUMOylation. Equal
amounts of bacterial expressed and puriﬁed E1, Ubc9 and SUMO1 or SUMO2
were added to the tubes and reaction started using 0.3 ml of 5mM ATP by
incubating at 32 C, 100min. Supernatant was discarded and beads were washed
once in EBC buffer before boiling the beads in 15 ml of 2 Simple Buffer for 5min
at 90 C.
Primary neuronal cultures and transfection. All in vivo experiments were
approved by the Cantonal Veterinary Ofﬁce of Zurich. Primary hippocampal
neuronal cultures from E17 rat embryos as described earlier17,18. The cells were
transfected by Lipofectamine 2000 (Life Technology) and CombiMag (OZ
Biosciences) as described earlier40, using 1 mg total plasmid DNA and incubated for
1 week (37 C, 5% CO2). Seven days post transfection (DIV8þ 7), neurons were
rinsed in PBS pH 7.4 and immediately ﬁxed in 4% paraformaldehyde (PFA) for
15min at RT and stained with appropriate antibodies.
Imaging of primary neurons. All the image acquisition and analysis was done
blind by different students to avoid experimenter bias. The images were analysed
from at least three to ﬁve independent transfections. Immunoﬂuorescence data
were acquired using confocal laser scanning microscope (LSM 700, Carl Zeiss)
using  40 lens (numerical aperture 1.4) and pinhole setup to 1 Airy unit and pixel
size of 90 nm. At least ten cells from three independent cultures were used for each
treatment and imaged as a z-stack (three to four optical sections) and 0.5 mm step
length. Image analysis and quantiﬁcation were performed using ImageJ software
(http://rsb.info.nih.gov/ij/), maximum intensity projections were created from the
z-stacks for analysis. Clusters were deﬁned using automatic threshold algorithm to
select region of interest. The Analyze Particles function in ImageJ was used to
count the number of cluster (area40.04 mm2) and measure their size (area in mm2).
To determine apposition to presynaptic terminal (vGAT puncta, secondary
channel), the size of the cluster was increased by 1 pixel all around. Apposition
between the threshold secondary channel and selected regions of interest in the
primary channel was considered as synaptic gephyrin cluster if apposition was
greater than 0.010 mm. Analysis of the generated data was plotted using Exel
software (Microsoft). Statistical signiﬁcance was analysed using Prism software.
Electrophysiology. Whole-cell voltage-clamp recordings were performed in
hippocampal cultured neurons (8þ 6 DIV) at RT and at a holding potential of
 60mV. Patch electrodes (3–4MO) were pulled from borosilicate glass and ﬁlled
with (in mM) 120 CsCl, 10 EGTA, 10 HEPES pH 7.4, 4 MgCl2, 0.5 GTP and
2 ATP. The external solution contained (in mM) 150 NaCl, 10 KCl, 2.0 CaCl2,
1.0 MgCl2, 10 HEPES pH 7.4 and 10 glucose. Recordings were performed using a
HEKA EPC-7 ampliﬁer and Patch Master v2.11 software (HEKA Elektronik,
Germany). Spontaneous GABAergic miniature postsynaptic currents (mIPSCs)
were isolated by adding CNQX (2 mM, Tocris), AP-5 (50 mM, Tocris) and
tetrodotoxin (0.1 mM, Tocris). After 3min of establishing the whole-cell mode,
mIPSCs occurring during a 1min interval and displaying amplitudes above
the background noise (6–12 pA) were identiﬁed and analysed ofﬂine using
MiniAnalysis 6.0.7 software (Synaptosoft). The decay phase of mIPSCs was ﬁtted
with a single exponential curve and both rise and decay phase were ﬁtted between
10 and 90% of its amplitude. For the average amplitude calculation, only cells with
more than 25–30 events in the recording period were included. However, for the
calculation of inter-event interval, cells with lower number of events were included,
as these may represent a loss of postsynaptic clusters.
Proximity ligation assay. In situ PLA was performed using the DuoLink II kit
(Olink Bioscience) according to the instructions of the manufacturer. The primary
antibody solution contained rabbit or mouse anti-GFP and rabbit or mouse
anti-Ac-Lys, anti-myc. The primary neurons in the coverslips were ﬁxed using 4%
PFA and later permeabilized using 0.2% Triton X-100. They were incubated in
primary antibody solution overnight at 4 C. The secondary antibodies conjugated
to oligonucleotides, PLA probes anti-Mouse MINUS and anti-Rabbit PLUS
(Duolink II, Olink Bioscinece) were diluted 1:5 in 10% normal goat serum (NGS)
(40 ml of PLA probe solution are needed per coverslip) and incubated for 20min at
RT. Later, 40 ml of PLA probe solution was pipetted on top of each coverslip
followed by incubation for 1 h at 37 C. The ligation solution was prepared
(Ligation (5 ) stock solution, 1:5 in H2O, Duolink II (Olink Bioscience); Ligase
(1U ml 1) stock solution, 1:40 in H2O, Duolink II (Olink Bioscience)). The ligation
solution was added to the coverslips (40ml per coverslip) and incubated for 1 h at
37 C. The coverslips were then washed two times for two minutes in Duolink II
Wash Buffer A. The ampliﬁcation solution (Ampliﬁcation Red (5 ) stock solu-
tion, 1:5 in H2O, Duolink II (Olink Bioscinece); Polymerase (10U ml 1) stock
solution, 1:80 in H2O, Duolink II (Olink Bioscience)) was prepared and added. The
coverslips were washed two times for 10min in Duolink II Wash Buffer B at RT.
Finally, coverslips were mounted on microscope slides with ﬂuorescence mounting
medium (Dako), to reduce fading of immunoﬂuorescence during microscopy.
Stereotactic brain surgery and 2-D08 injection. All in vivo experiments were
approved by the Cantonal Veterinary Ofﬁce of Zurich.
Eight- to 10-week-old mice (both male and female) were used for the study.
A 5 cm-long glass pipette (Ø ca. 50–60 mm at the tip) was buffered with Mineral Oil
(Sigma Cell Culture, d¼ 0.84 gml 1) and then attached to the injection apparatus
(Drummond Scientiﬁc Company) to take up 10 ml of 2-D08 (Sigma, 30 mM)
or NaCl.
To anaesthetize the mice, they were put in a closed box (Indulab AG, Gams,
CH) with a gas supply, where isoﬂurane diluted in O2 (mixer used, Northern
vaporizers) was introduced. Once the animal did not respond to common pain
stimuli anymore, the head was stably ﬁxed in place in the Kopf stereotaxic setup
(Model 900 Small Animal Stereotaxic Instrument). During surgery, the isoﬂurane
concentration was reduced to 2–4%. Mice were kept on a warm pad during and
after surgery, to prevent a drastic cooling of the body temperature. To prevent eyes
from drying out, they were covered with Vitamin A (Bausch&Lomb Swiss AG).
Craniotomy was performed in the right hemisphere (stereotactic coordinates:
anteroposterior  1.8mm, lateral þ 1.6mm, dorsoventral þ 1.9mm) using a drill
(Model SR, Foredom Electric Co., Bethel, CT, USA). Mice received a unilateral
stereotaxic injection of 70 nl 2-D08 or NaCl into the dorsal hippocampus. To allow
2-D08 (or NaCl) diffusion, there was a 2min interval between the injection and the
removal of the capillary.
Afterwards, the skin was sewed with three stitches and a monoﬁbrillar suture.
Mice were intraperitoneally (i.p.) injected with 1mg kg 1 buprenorphine
Temgesic (Reckitt Benckiser, CH, LOT 5348, 1:10 in NaCl) and were then allowed
to recover in a separate, warmed cage until they resumed their normal behaviour.
The mice were perfused 24 h post injection post surgery for morphology analysis.
In-utero electroporation and tissue preparation. All in vivo experiments were
approved by the Cantonal Veterinary Ofﬁce of Zurich.
Timed-pregnant mothers (14 days) were anaesthetized with isoﬂurane in
oxygen carrier. Uteri were exposed through a 2 cm incision in the ventral
peritoneum. Embryos were carefully lifted using ring forceps through the incision
and placed on humidiﬁed gauze pads. pCAG-LoxP-Stop-LoxP-eGFPC2-gephyrin,
pCAG-LoxP-Stop-LoxP-eGFPC2-K148R and pCAG-LoxP-Stop-LoxP-eGFPC2-
K724R were co-injected with pCAG-LoxP-Stop-LoxP-tdTomato and pCAG-
ERT2CreERT2 (total concentration 3 mgml 1, prepared using Endo Free plasmid
puriﬁcation kit) mixed with 0.05% Fast Green (Sigma) was injected through the
uterine wall into the telencephalic vesicle using pulled borosilicate needles and a
Femtojet microinjector (VWR). Five electrical pulses were applied at 50V (50ms
duration) across the uterine wall at 1 s intervals using 5mm platinum tweezer
electrodes (CUY650P5, Nepagene) and an ECM-830 BTX square wave
electroporator (BTX, Gentronic, Inc.). The uterine horns were then replaced in the
abdominal cavity, and the abdomen wall and skin were sutured using surgical
needle and thread. The pregnant mouse was injected with buprenorphine
(Vetergesic; Alstoe Ltd) and warmed on heating pad until it woke up. The whole
procedure was complete within 30min. Conditional expression of the
electroporated proteins was archived by i.p. administration of 50 ml 1mM
tamoxifen at postnatal day 10. Mice were anaesthetized with pentobarbital
(Nembutal; 60mg kg 1, i.p.) and perfused transcardially with 20ml PBS pH 7.4 to
ﬂush the blood away at P15, followed by 60ml ice-cold ﬁxative solution (4% PFA,
0.15M NaH2PO4, 15% saturated picric acid pH 7.4). After perfusion, brains were
rapidly dissected and postﬁxed in 50ml using 4% PFA for 3 h and rinsed with PBS
before transferring to 30% sucrose in PBS overnight 4 C. The brains were frozen in
powered dry ice and stored at  80 C. The brains were cut with the sliding
microtome 40mm-thick and stored in anti-freeze solution (50mM phosphate
buffer, 15% glucose, 30% v/v ethylene glycol, sodium azide pH 7.4) and stored at
 20 C. Sections, stored in anti-freeze solution, were washed twice for 10min in
Tris-buffered saline (pH 7.4) in 12-well culture plates. The sections were incubated
in primary antibody diluted in PBS pH 7.4 containing 2% NGS and 0.2% Triton
X-100 using nine-well glass plates in a moist chamber overnight at 4 C at
100 r.p.m. The day after, sections were washed three times 10min in PBS pH 7.4
and incubated in secondary antibodies diluted in PBS pH 7.4 containing 2% NGS
for 30min at RT in shaker. The sections were washed again three times 10min in
PBS pH 7.4, mounted on gelatinized glass slides and mounted using DAKO
mounting media for confocal image analysis.
Data availability. All data generated or analysed during this study are included in
this published article (and its Supplementary Information ﬁles) or are available
from the author upon request.
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